In recent years, numerous genetic alterations have been identified in high-grade gliomas (HGGs), with key driver mutations involving IDH, EGFR, TERT, PTEN, TP53, ALK, and ROS1, which serve as critical hub proteins in glioma tumorigenesis [13,14]. This evidence concerns the gene IDH1 and central nervous system cancer.